$REGN
REGENERON PHARMACEUTICALS, INC.

2017 Q3 Form 10-Q Financial Statement

#000153217617000034 Filed on November 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3
Revenue $1.501B $1.220B
YoY Change 22.99% 7.27%
Cost Of Revenue $46.39M $29.90M
YoY Change 55.14% -55.5%
Gross Profit $1.454B $1.190B
YoY Change 22.19% 11.21%
Gross Profit Margin 96.91% 97.55%
Selling, General & Admin $306.8M $270.0M
YoY Change 13.6% 28.6%
% of Gross Profit 21.09% 22.69%
Research & Development $529.7M $543.0M
YoY Change -2.45% 27.5%
% of Gross Profit 36.43% 45.63%
Depreciation & Amortization $37.80M $27.80M
YoY Change 35.97% 34.3%
% of Gross Profit 2.6% 2.34%
Operating Expenses $836.5M $813.1M
YoY Change 2.88% 27.86%
Operating Profit $559.9M $362.8M
YoY Change 54.33% -7.55%
Interest Expense $6.182M -$496.0K
YoY Change -1346.37% -128.92%
% of Operating Profit 1.1% -0.14%
Other Income/Expense, Net $5.679M $3.079M
YoY Change 84.44% 255.13%
Pretax Income $565.6M $365.9M
YoY Change 54.59% -6.97%
Income Tax $177.3M $101.1M
% Of Pretax Income 31.34% 27.63%
Net Earnings $388.3M $264.8M
YoY Change 46.64% 25.86%
Net Earnings / Revenue 25.88% 21.7%
Basic Earnings Per Share $3.64 $2.53
Diluted Earnings Per Share $3.32 $2.27
COMMON SHARES
Basic Shares Outstanding 106.7M shares 104.8M shares
Diluted Shares Outstanding 117.0M shares 116.5M shares

Balance Sheet

Concept 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.379B $1.408B
YoY Change -2.06% 57.14%
Cash & Equivalents $792.1M $920.4M
Short-Term Investments $587.0M $488.0M
Other Short-Term Assets $357.0M $179.0M
YoY Change 99.44% -1.65%
Inventory $641.6M $345.6M
Prepaid Expenses
Receivables $1.533B $1.332B
Other Receivables $0.00 $0.00
Total Short-Term Assets $4.136B $3.502B
YoY Change 18.11% 30.87%
LONG-TERM ASSETS
Property, Plant & Equipment $2.275B $1.872B
YoY Change 21.49% 26.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.327B $778.0M
YoY Change 70.57% 14.24%
Other Assets $36.62M $20.71M
YoY Change 76.86% 351.78%
Total Long-Term Assets $4.565B $3.326B
YoY Change 37.25% 32.67%
TOTAL ASSETS
Total Short-Term Assets $4.136B $3.502B
Total Long-Term Assets $4.565B $3.326B
Total Assets $8.701B $6.828B
YoY Change 27.43% 31.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $154.0M $124.0M
YoY Change 24.19% 15.89%
Accrued Expenses $538.0M $435.0M
YoY Change 23.68% -7.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $1.139B $961.2M
YoY Change 18.46% 30.78%
LONG-TERM LIABILITIES
Long-Term Debt $702.0M $382.0M
YoY Change 83.77% -3.29%
Other Long-Term Liabilities $125.2M $135.7M
YoY Change -7.72% 74.18%
Total Long-Term Liabilities $125.2M $135.7M
YoY Change -7.72% 74.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.139B $961.2M
Total Long-Term Liabilities $125.2M $135.7M
Total Liabilities $2.650B $2.337B
YoY Change 13.39% 23.9%
SHAREHOLDERS EQUITY
Retained Earnings $2.773B $1.495B
YoY Change 85.49% 114.29%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $316.2M $316.1M
YoY Change 0.06% 9.45%
Treasury Stock Shares 3.764M shares 3.762M shares
Shareholders Equity $6.052B $4.491B
YoY Change
Total Liabilities & Shareholders Equity $8.701B $6.828B
YoY Change 27.43% 31.74%

Cashflow Statement

Concept 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income $388.3M $264.8M
YoY Change 46.64% 25.86%
Depreciation, Depletion And Amortization $37.80M $27.80M
YoY Change 35.97% 34.3%
Cash From Operating Activities $414.9M $651.0M
YoY Change -36.27% -27.09%
INVESTING ACTIVITIES
Capital Expenditures -$59.70M -$118.6M
YoY Change -49.66% -18.82%
Acquisitions
YoY Change
Other Investing Activities -$299.3M -$287.3M
YoY Change 4.18% 109.71%
Cash From Investing Activities -$358.8M -$405.8M
YoY Change -11.58% 43.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -8.200M 28.70M
YoY Change -128.57% -108.3%
NET CHANGE
Cash From Operating Activities 414.9M 651.0M
Cash From Investing Activities -358.8M -405.8M
Cash From Financing Activities -8.200M 28.70M
Net Change In Cash 47.90M 273.9M
YoY Change -82.51% 3.75%
FREE CASH FLOW
Cash From Operating Activities $414.9M $651.0M
Capital Expenditures -$59.70M -$118.6M
Free Cash Flow $474.6M $769.6M
YoY Change -38.33% -25.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
dei Document Type
DocumentType
10-Q
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
30000 USD
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
REGENERON PHARMACEUTICALS INC
dei Entity Central Index Key
EntityCentralIndexKey
0000872589
CY2017Q1 regn Aggregatefundingadvancedbytheparticipants
Aggregatefundingadvancedbytheparticipants
720000000 USD
CY2015Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
50700000 USD
CY2016Q3 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
33900000 USD
CY2016Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
28200000 USD
CY2017Q3 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
24500000 USD
CY2016Q4 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
91753000 USD
CY2017Q3 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
119608000 USD
CY2016Q4 regn Accruedsalesrelatedchargesdeductionsandroyalties
Accruedsalesrelatedchargesdeductionsandroyalties
159985000 USD
CY2017Q3 regn Accruedsalesrelatedchargesdeductionsandroyalties
Accruedsalesrelatedchargesdeductionsandroyalties
167467000 USD
CY2016Q4 regn Capitalandfacilityleaseobligationscurrent
Capitalandfacilityleaseobligationscurrent
129557000 USD
CY2017Q3 regn Capitalandfacilityleaseobligationscurrent
Capitalandfacilityleaseobligationscurrent
0 USD
CY2016Q4 regn Capitalandfacilityleaseobligationsnoncurrent
Capitalandfacilityleaseobligationsnoncurrent
351569000 USD
CY2017Q3 regn Capitalandfacilityleaseobligationsnoncurrent
Capitalandfacilityleaseobligationsnoncurrent
702317000 USD
CY2016Q3 regn Costofmanufacturing
Costofmanufacturing
14327000 USD
regn Costofmanufacturing
Costofmanufacturing
74923000 USD
CY2017Q3 regn Costofmanufacturing
Costofmanufacturing
57844000 USD
regn Costofmanufacturing
Costofmanufacturing
141547000 USD
CY2016Q4 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
115267000 USD
CY2017Q3 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
187036000 USD
CY2016Q4 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
503474000 USD
CY2017Q3 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
408786000 USD
CY2016Q3 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
479000 shares
regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
474000 shares
CY2017Q3 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
513000 shares
regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
500000 shares
CY2016Q3 regn Other Collaboration Revenue
OtherCollaborationRevenue
191298000 USD
regn Other Collaboration Revenue
OtherCollaborationRevenue
562786000 USD
CY2017Q3 regn Other Collaboration Revenue
OtherCollaborationRevenue
236625000 USD
regn Other Collaboration Revenue
OtherCollaborationRevenue
640919000 USD
CY2017Q1 regn Reimbursementreceivedbythe Company
ReimbursementreceivedbytheCompany
57000000 USD
CY2016Q4 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
175263000 USD
CY2017Q3 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
221278000 USD
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
879096000 USD
CY2017Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
818426000 USD
CY2016Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
134984000 USD
CY2017Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
153946000 USD
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1343368000 USD
CY2017Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1532693000 USD
CY2016Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
92989000 USD
CY2017Q3 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
217478000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12840000 USD
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
23835000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3029993000 USD
CY2017Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3570673000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
453110000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-284829000 USD
CY2016Q4 us-gaap Assets
Assets
6973466000 USD
CY2017Q3 us-gaap Assets
Assets
8701215000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
3180188000 USD
CY2017Q3 us-gaap Assets Current
AssetsCurrent
4135742000 USD
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
1367741000 USD
CY2017Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
1914182000 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6241000 USD
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
33634000 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
18987000 USD
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3344000 USD
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
1380487000 USD
CY2017Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
1883892000 USD
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
58000 USD
CY2017Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
634000 USD
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
18987000 USD
CY2017Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
3344000 USD
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
920357000 USD
CY2017Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
938360000 USD
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
18929000 USD
CY2017Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2710000 USD
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
883950000 USD
CY2017Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
820872000 USD
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
36407000 USD
CY2017Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
117488000 USD
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
815041000 USD
CY2017Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
1239263000 USD
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
503481000 USD
CY2017Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
586879000 USD
CY2016Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1318522000 USD
CY2017Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1826142000 USD
us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
-3300000 USD
CY2017Q3 us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
6400000.0 USD
us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
6500000.0 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
201200000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
809102000 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
920359000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
535203000 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
792065000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
111257000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
256862000 USD
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
256701000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
630936000 USD
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
409804000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1061667000 USD
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
29901000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
150090000 USD
CY2017Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
46388000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
149774000 USD
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
857320000 USD
us-gaap Costs And Expenses
CostsAndExpenses
2649862000 USD
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
940747000 USD
us-gaap Costs And Expenses
CostsAndExpenses
2749000000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
116397000 USD
CY2017Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
132832000 USD
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
327298000 USD
CY2017Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
274666000 USD
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
825303000 USD
CY2017Q3 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
927023000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
75845000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
110960000 USD
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.14
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.66
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.51
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.84
CY2016Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.276
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.350
CY2017Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.313
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.327
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
153086000 USD
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
166102000 USD
CY2017Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2016Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 USD
CY2017Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 USD
CY2016Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 USD
CY2017Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 USD
us-gaap Gain Loss On Interest Rate Cash Flow Hedge Ineffectiveness
GainLossOnInterestRateCashFlowHedgeIneffectiveness
0 USD
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
365881000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
988288000 USD
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
565605000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1523744000 USD
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
101077000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
345881000 USD
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
177288000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
498752000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
107438000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-28908000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
176079000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
359829000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
190327000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
108242000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
282176000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-59116000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
99706000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
235645000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-34857000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
28209000 USD
CY2016Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
998000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1086000 shares
CY2017Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2016Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
81000 shares
CY2017Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2016Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10156000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10340000 shares
CY2017Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9809000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9386000 shares
CY2016Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-496000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4387000 USD
CY2017Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-6182000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-19084000 USD
CY2016Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 USD
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
397000 USD
CY2017Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 USD
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 USD
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
13334000 USD
CY2017Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
23958000 USD
CY2016Q4 us-gaap Inventory Net
InventoryNet
399356000 USD
CY2017Q3 us-gaap Inventory Net
InventoryNet
641588000 USD
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
92287000 USD
CY2017Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
187029000 USD
CY2016Q3 us-gaap Inventory Write Down
InventoryWriteDown
5000000 USD
us-gaap Inventory Write Down
InventoryWriteDown
11300000 USD
CY2017Q3 us-gaap Inventory Write Down
InventoryWriteDown
5400000 USD
us-gaap Inventory Write Down
InventoryWriteDown
14500000 USD
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
202301000 USD
CY2017Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
217448000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
2524221000 USD
CY2017Q3 us-gaap Liabilities
Liabilities
2649622000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6973466000 USD
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8701215000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1241495000 USD
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1138628000 USD
CY2016Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
503481000 USD
CY2017Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
586879000 USD
CY2016Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
864260000 USD
CY2017Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1327303000 USD
CY2016Q3 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
CY2017Q3 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-208712000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
186135000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-775548000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-669436000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1095517000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
740163000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
264804000 USD
us-gaap Net Income Loss
NetIncomeLoss
642407000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
388317000 USD
us-gaap Net Income Loss
NetIncomeLoss
1024992000 USD
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
264804000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
642804000 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
388317000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1024992000 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3079000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4550000 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5679000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17036000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
362802000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
983738000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
559926000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1540780000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
103512000 USD
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
84691000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20294000 USD
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
36618000 USD
CY2016Q3 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
0 USD
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
0 USD
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
2000 USD
CY2016Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8103000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11471000 USD
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
21485000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
36645000 USD
CY2016Q4 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
91434000 USD
CY2017Q3 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
213153000 USD
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1178000 USD
CY2017Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
334000 USD
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
100385000 USD
CY2017Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
125225000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-13586000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-44016000 USD
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3575000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8937000 USD
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11861000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2048000 USD
CY2016Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
26964000 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
67445000 USD
CY2017Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
61506000 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
231446000 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
242117000 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
46954000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
77832000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
606153000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
883748000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
361486000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
164963000 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
130528000 USD
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
143761000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
89777000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
226892000 USD
us-gaap Proceeds From Repayments Of Long Term Debt And Capital Securities
ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
5085000 USD
us-gaap Proceeds From Repayments Of Long Term Debt And Capital Securities
ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
57000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
192091000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
379275000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2083421000 USD
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2274529000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
12650000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
1853000 USD
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
19925000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
543047000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1573089000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
529749000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1547159000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1748222000 USD
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2773214000 USD
CY2016Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
144392000 USD
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
527500000 USD
CY2017Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
245175000 USD
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
677670000 USD
CY2016Q3 us-gaap Revenues
Revenues
1220122000 USD
us-gaap Revenues
Revenues
3633600000 USD
CY2017Q3 us-gaap Revenues
Revenues
1500673000 USD
us-gaap Revenues
Revenues
4289780000 USD
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
857468000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
2475869000 USD
CY2017Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
957367000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
2739745000 USD
CY2016Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
270045000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
851760000 USD
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
306766000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
910520000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
405320000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
380144000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
4449245000 USD
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
6051593000 USD
CY2016Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
235776000 USD
CY2017Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
126612000 USD
CY2016Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
3763868 shares
CY2017Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
3763868 shares
CY2016Q4 us-gaap Treasury Stock Value
TreasuryStockValue
316240000 USD
CY2017Q3 us-gaap Treasury Stock Value
TreasuryStockValue
316240000 USD
CY2015Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
55249000 USD
CY2016Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
37753000 USD
CY2016Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
45851000 USD
CY2017Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
75301000 USD
us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
200077000 USD
us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
295977000 USD
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
217573000 USD
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
266527000 USD
CY2017Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
10322000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
9886000 shares
CY2016Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
11633000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
11981000 shares
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116466000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116567000 shares
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
117028000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115994000 shares
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
104833000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
104586000 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106706000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106108000 shares
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Standards </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update 2014-09 ("ASU 2014-09"), </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which, along with subsequent amendments to ASU 2014-09 issued by the FASB, will replace existing revenue recognition guidance. The new standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. To achieve that core principle, an entity must identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when (or as) the entity satisfies the performance obligation. The new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption is permitted, but no earlier than 2017 for calendar year-end entities. The standard allows for two transition methods - retrospectively to each prior reporting period presented (full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption (modified retrospective method). The Company has substantially completed its impact assessment, and does not currently expect the new standard to have a material impact on total revenues. However, substantive development milestones, which were previously recognized in the period when the milestone was achieved, will be recognized over the remaining performance period under the new standard. In connection with adopting the new standard, the Company does not anticipate implementing changes to its systems or internal controls. The Company expects to adopt the standard using the modified retrospective method, and continues to evaluate the impact of the new guidance on its financial statement disclosures.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued Accounting Standards Update 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">. The amendments require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The implementation of the amendments is expected to increase the volatility of the Company's net income, as the Company holds publicly traded equity investments; however, the Company is not able to estimate the impact of adopting these amendments, as the significance of the impact will depend on the Company's equity investment balance upon adoption.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued Accounting Standards Update 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. The new standard requires a lessee to recognize in its balance sheet (for both finance and operating leases) a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on the Company's financial statements, including related disclosures. The Company expects the new standard will have a significant impact on its internal controls, systems, and processes.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued Accounting Standard Update 2017-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging: Targeted Improvements to Accounting for Hedging Activities</font><font style="font-family:inherit;font-size:10pt;">. The amendments expand and refine hedge accounting for both financial and non-financial risk components, align the recognition and presentation of the effects of hedging instruments and hedge items in the financial statements, and include certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company does not expect the implementation of the amendments to have an impact on the Company's financial statements in connection with its current derivative instruments.</font></div></div>
us-gaap Revenue Recognition Revenue Reductions
RevenueRecognitionRevenueReductions
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks, distribution-related fees, and other sales-related deductions. </font></div></div>

Files In Submission

Name View Source Status
0001532176-17-000034-index-headers.html Edgar Link pending
0001532176-17-000034-index.html Edgar Link pending
0001532176-17-000034.txt Edgar Link pending
0001532176-17-000034-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
regn-093017x10q.htm Edgar Link pending
regn-20170930.xml Edgar Link completed
regn-20170930.xsd Edgar Link pending
regn-20170930_cal.xml Edgar Link unprocessable
regn-20170930_def.xml Edgar Link unprocessable
regn-20170930_lab.xml Edgar Link unprocessable
regn-20170930_pre.xml Edgar Link unprocessable
regn-ex_311x09302017x10q.htm Edgar Link pending
regn-ex_312x09302017x10q.htm Edgar Link pending
regn-ex_32x09302017x10q.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending